{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Peptide Show","title":"Dylan Gemelli: Can you trust the peptides you’re buying?","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/c26256ee\"></iframe>","width":"100%","height":180,"duration":1843,"description":"What happens when the people profiting from peptides have different motives from the people relying on them?  \n\nFor the past 15 years, the fitness and biohacking educator and host of The Dylan Gemelli Podcast has watched peptides move from bodybuilding forums and research chemical sites into the mainstream.\nThen the market changed around him.\nGLP-1s propelled peptides into public consciousness. BPC-157 became one of the compounds most closely associated with the category. And an underground market expanded alongside them, where suppliers, testing and certificates of analysis can create an appearance of certainty that may not always be justified.\nGemelli believes peptides have far more potential than the handful of compounds dominating the conversation. But he is equally concerned by what happens when consumers buy from unregulated suppliers, assume a COA proves quality, or trust that what is on the label is what is actually in the vial.\nHe explains:\n\n■ How peptides went from obscure research chemicals to the mainstream\n■ Why GLP-1s and BPC-157 have narrowed the public understanding of peptides\n■ Why a certificate of analysis does not necessarily prove what is actually in the vial\n■ What consumers should understand about underground suppliers, raw materials and peptide testing\n■ Why he believes peptides will become more widely accepted, and why he worries about who ultimately controls them\nChapters\n\n\nFurther reading\n\nFDA: Concerns around unapproved GLP-1 drugs, foreign APIs, illegal online sales and products marketed as being for research purposes: FDA: Concerns with unapproved GLP-1 drugs \nFDA: July 2026 Pharmacy Compounding Advisory Committee meeting covering BPC-157, KPV, TB-500, MOTS-c and other peptide-related bulk substances: FDA PCAC July 2026 meeting \n\nFollow Dylan Gemelli\n\nInstagram: Instagram.com/dylangemelli\nX: x.com/DylanGemelli\nYouTube: YouTube.com/@DylanGemelliBiohacking\nWebsite: DylanGemelli.com\n\nFollow Richard Skaife\n\nLinkedIn:...","thumbnail_url":"https://img.transistorcdn.com/QcXtaDr9qe6jHT4c0BxQri4VufvdedcvMTMLmbuyqSA/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mZTg2/YmYyODMzN2NhMDNh/NzMzZGUxMzJhNDFj/YjVmMS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}